The primary hurdle to the widespread adoption of genomic medicine has historically been the cost. However, the economic landscape of 2026 looks very different. Health insurers and national health services are beginning to see the "long-term value" of NGS. By providing an accurate diagnosis earlier, NGS prevents patients from undergoing multiple, ineffective treatments and reduces the number of...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek